TARS Q2 2025 Earnings — Tarsus Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

TARSTarsus Pharmaceuticals, Inc.

$3B

Q2 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$103M+151.5% YoY

Gross Profit

$96M93.9% margin

Operating Income

-$22M-21.6% margin

Net Income

-$20M-19.8% margin

EPS (Diluted)

$-0.48

QoQ Revenue Growth

+31.1%

Cash Flow

Operating Cash Flow

-$29M

Free Cash Flow

-$30M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$495M

Total Liabilities

$162M

Stockholders' Equity

$333M

Cash & Equivalents

$97M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$103M	$41M	+151.5%
Gross Profit	$96M	$38M	+155.0%
Operating Income	-$22M	-$33M	+33.4%
Net Income	-$20M	-$33M	+38.9%

Revenue Segments

Product

$103M100%